Symptoms reported in CD individuals with or without anti-SARS-Cov-2 antibodies are reported in Fig.?3. Table 2 Clinical and demographic characteristics of celiac patients with or without anti-SARS-CoV-2 Ig.
Sex, female (%)16 (80)72 (81)1.0Age at enrolment (years)471344150.54Age at diagnosis (years)341733160.80BMI (kg/cm2)23.5??5.822.4??3.80.29COVID-19-like symptoms, n (%)9 (80)17 (19)0.02Positive anti-transglutaminase IgA (%)5 (25)17 (19)0.54Non-adherence to GFD and/or positive urinary GIP (%)0 (0)5 (6)0.58Duodenal atrophy (Marsh 3a, 3b, 3c) (%)7 (35)29 (32)1.0Refractory celiac disease (%)0 (0)2 (2)1.0Presence of an AI comorbidity (%)2 (10)17 (19)0.51 Open in a separate window AI, autoimmune; Rabbit polyclonal to ALKBH1 BMI, body mass LHF-535 index; GFD, gluten-free diet; GIP, gluten immunogenic peptides. CD individuals with anti-SARS-CoV-2 Ig were asked to undergo a nasopharyngeal swab RT-PCR and 1 asymptomatic patient had a positive result. 3.3. regarded as statistically significant. Of the 20 CD individuals with IgA and/or IgG in serum, 9/20 (45%) were referred for COVID-19-like symptoms. The medical, serological and histological characteristics of the individuals are reported in Table?2 . Twenty-six (62%) of the 42 individuals with COVID-19 symptoms underwent the serological test and 9/26 (34%) offered anti-SARS-CoV-2 Ig. No anti-SARS-CoV-2 Ig were recognized in 17/26 (66%) tested individuals who reported COVID-19-like symptoms. Symptoms reported in CD individuals with or without anti-SARS-Cov-2 antibodies are reported in Fig.?3. Table 2 Clinical and demographic characteristics of celiac individuals with or without anti-SARS-CoV-2 Ig.
Sex, female (%)16 (80)72 (81)1.0Age at enrolment (years)471344150.54Age at diagnosis (years)341733160.80BMI (kg/cm2)23.5??5.822.4??3.80.29COVID-19-like symptoms, n (%)9 (80)17 (19)0.02Positive anti-transglutaminase IgA (%)5 (25)17 (19)0.54Non-adherence to GFD and/or positive urinary GIP (%)0 (0)5 (6)0.58Duodenal atrophy (Marsh 3a, 3b, 3c) (%)7 (35)29 (32)1.0Refractory celiac disease (%)0 (0)2 (2)1.0Presence of an AI comorbidity (%)2 (10)17 (19)0.51 Open in a separate window AI, autoimmune; BMI, body mass index; GFD, gluten-free diet; GIP, gluten immunogenic peptides. CD individuals with anti-SARS-CoV-2 Ig were asked to undergo a nasopharyngeal swab RT-PCR and one asymptomatic individual experienced a positive effect. 3.3. Intestinal ACE2 receptor Generally, the ACE2 receptor was present within the luminal surface of duodenal villi in CD individuals with no indications of atrophy with an average percentage of positive cells of 55% (range 20C80%; Fig.?4 A); conversely, when duodenal atrophy was present, ACE2 was weakly or not expressed within the enteric cells (Fig.?4B). Interestingly, we observed that ACE2 manifestation was more intense at the tip of the villi and less intense in the crypts. This result, although initial, may suggest that ACE2 manifestation has a gradient in the enteric mucosa?along the villous-crypt axis. Open in a separate windowpane Fig. 4 Representative images of ACE2 manifestation in the non-atrophic (inactive; A) and an active (B) duodenal mucosa of a CD patient. Scale pub, 100?m. All the analyzed duodenal samples are from CD individuals with bad anti-SARS-CoV-2 serology not reporting a earlier infection. 4.?Conversation The present study is the first attempt to investigate the effects of the SARS-CoV-2 pandemic on CD individuals and their immunological response to viral illness. The serological anti-SARS-CoV-2 Ig LHF-535 profiles of CD individuals are similar to those of non-CD individuals. Moreover, the presence of CD biomarkers (tTGA, duodenal atrophy), autoimmune comorbidities and GFD adherence do not appear to influence the immune response in CD subjects. In the investigated cohort of individuals, COVID-19 symptoms were much like those explained in the literature, with a single case of hospitalization for slight respiratory distress. More than 80% of the CD individuals experienced a stress-related illness and may need extra support because of the pandemic. Beside CD, the reported rate could be related to the high incidence of COVID-19 in the analyzed region and the high percentage of female sex in the cohort of individuals [21,22]. The present findings are of particular relevance as they were from an area badly affected by the SARS-CoV-2 pandemic, with all individuals living in the MilanCBergamo part of Northern Italy [21] and 20% screening positive for anti-SARS-CoV-2 Ig. Half of individuals with LHF-535 positive anti-SARS-CoV-2 serology reported symptoms, while others did not possess any symptoms, suggesting asymptomatic disease. The presence of symptomatic individuals with bad for anti-SARS-CoV-2 Ig suggests that additional factors could be involved in the individuals clinical picture. Regrettably, during the 1st lockdown, very few nasopharyngeal swabs were taken, including in private hospitals, due to a shortage of resources and, consequently, PCR results are not available to confirm or refute the findings [21]. However, serological testing has been used in recent weeks to monitor viral spread in the general human population and among individuals at increased risk of contracting COVID-19, including immunosuppressed individuals [23]. Here, we used a test from the laboratory of Professor Krammer [17,18] that experienced received FDA authorization [17], [18], [19]. The assay showed superb specificity and level of sensitivity [19,23]. Interesting, the IgA response against SARS-CoV-2 has been reported to be possibly associated with a mucosal immune response in the gut and lungs [24]. A recent paper suggested that IgA production might occur locally at mucosal sites, probably correlating with viral weight, the duration of viral exposure and disease access route [25]. In line with this suggestion, it has been demonstrated recently.